Vertex Pharmaceuticals Logo

Email this page: News Release

Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks

For security reasons, registration is required before you can use this feature.
* Indicates required field